Potential Theranostic Boron Neutron Capture Therapy Agents as Multimodal Radiopharmaceuticals.

Area of Science:

• Oncology
• Radiopharmaceutical Chemistry
• Medical Physics

Background:

• Boron neutron capture therapy (BNCT) is an established cancer treatment modality.
• Current BNCT primarily uses boronophenylalanine as the boron-containing drug.
• Fluorine-18 (F-18) radiolabeled analogs are increasingly used for targeting and monitoring in BNCT.

Purpose of the Study:

• To explore the development of novel tumor-specific BNCT agents.
• To investigate multimodal approaches combining imaging and therapy.
• To discuss future radiopharmaceutical design for BNCT.

Main Methods:

• Review of existing BNCT drugs and radiolabeling techniques.
• Analysis of emerging tumor-targeting moieties (peptides, ligands, immunomolecules).
• Discussion of boron-rich compounds (sodium borocaptate, carboranes) for BNCT applications.

Main Results:

• New therapeutic radiopharmaceuticals offer opportunities for targeted BNCT agents.
• Radiolabeled BNCT agents can support simultaneous imaging and therapy (theranostics).
• Combination of boron moieties with targeting agents shows promise for BNCT.

Conclusions:

• Advancements in drug design and tumor targeting are crucial for next-generation BNCT agents.
• Multimodal theranostic applications are feasible with advanced radiopharmaceuticals.
• Future BNCT development focuses on locoregional cancers like head and neck cancer.